Select Page

Plexium Launches with $28 Million Series A

Plexium has landed $28 million in Series A financing to launch a proprietary platform that can identify novel therapeutics that can modulate protein degradation to treat cancer and neurodegenerative diseases. The platform technology, dubbed DELPhe, takes advantage of...

Merck Acquires Neurodegenerative Biotech Calporta

Merck has acquired Calporta Therapeutics, Inc., a San Diego biotech focused on developing drugs that support lysosome function, which could combat diseases (including Alzheimer’s and Parkinson’s disease) linked to the toxic buildup of certain protein molecules. The...

Pin It on Pinterest